Managing AF Related Stroke
The most common treatment for managing AF-related stroke risk is the use of blood thinning medications, such as warfarin.
Surgical removal of the left atrial appendage (LAA) has been performed for more than 70 years. Although it is an established procedure, surgical LAA resection is an invasive, open-heart procedure and the sutures or staples often fail to demonstrate consistent closure across patients.
With the known challenges of surgical LAA resection, a less invasive device-based solution may provide alternative protection against the migration of blood clots in certain patients with AF.
Left Atrial Appendage Closure (LAAC)
Left Atrial Appendage Closure (LAAC) is a device alternative to oral anticoagulation therapy in patients with non-valvular atrial fibrillation. Patients with AF are at a significantly greater risk of having a stroke due to migration of clots that may form in the left atrial appendage (LAA). By securely closing off the LAA, the device is designed to reduce the risk of stroke, cardiovascular death and systemic embolization, potentially eliminating the need for long-term warfarin therapy. The elimination of oral anticoagulants may also result in a reduction of bleeding-related events such as bruising, nose bleeds, gastrointestinal bleeding, and more importantly, hemorrhagic strokes.